2
The Institute for Clinical and Economic Review (ICER) released a report on Monday assessing the clinical effectiveness and value of GSK Plc’s (NYSE:GSK) chronic obstructive pulmonary disease (COPD) treatments, Trelegy Ellipta and Breo Ellipta.
Under the Inflation Reduction Act, CMS is negotiating prices for select Medicare Part D drugs. In the current cycle, Trelegy Ellipta and Breo Ellipta are among the medications under review, alongside 15 other drugs slated for pricing changes in 2027.
The findings will be submitted to the Centers for Medicare & Medicaid Services (CMS) as part of ongoing Medicare drug price negotiations.
Also Read: GSK’s Twice-Yearly Depemokimab …
